Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 10:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–8 of 8 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: DNL151 Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to See How BIIB122 Works in the Human Body, and to Evaluate it's Safety, and Tolerability in Healthy Adult Japanese, Chinese, and Caucasian Participants

NCT05229562
View directory record Official record
Conditions
Healthy Volunteer
Interventions
BIIB122
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Apr 17, 2023 · Synced Sep 2, 2026, 10:14 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Determine the Absolute Bioavailability of BIIB122/DNL151 in Healthy Subjects

NCT05005338
View directory record Official record
Conditions
Healthy Volunteers
Interventions
BIIB122 (DNL151), [14C] BIIB122 ([14C] DNL151)
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 50 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 16, 2021 · Synced Sep 2, 2026, 10:14 PM EDT
Terminated Phase 3 Interventional Results available

A Study to Assess if BIIB122 Tablets Are Safe and Can Slow Worsening of Early-Stage Parkinson's Disease in Participants With Specific LRRK2 Genetic Variants Between the Ages of 30 and 80 Using the Movement Disorder Society-Unified Parkinson's Disease Rating Scale

NCT05418673
View directory record Official record
Conditions
Parkinson Disease
Interventions
BIIB122, BIIB122-Matching Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
30 Years to 80 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
12
States / cities
San Francisco, California • Aurora, Colorado • Englewood, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2024 · Synced Sep 2, 2026, 10:14 PM EDT
Completed Phase 1 Interventional

Study to Evaluate DNL151 in Subjects With Parkinson's Disease

NCT04056689
View directory record Official record
Conditions
Parkinson's Disease
Interventions
DNL151, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
30 Years to 75 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
2
States / cities
Orlando, Florida • Farmington Hills, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 17, 2023 · Synced Sep 2, 2026, 10:14 PM EDT
Active, not recruiting Phase 2 Interventional

Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD)

NCT06602193
View directory record Official record
Conditions
Parkinson Disease
Interventions
BIIB122 225 mg, BIIB122-Matching Placebo
Drug · Other
Lead sponsor
Denali Therapeutics Inc.
Industry
Eligibility
30 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
7
States / cities
Los Angeles, California • San Francisco, California • Boca Raton, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Sep 2, 2026, 10:14 PM EDT
Completed Phase 2 Interventional

A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80

NCT05348785
View directory record Official record
Conditions
Parkinson Disease
Interventions
BIIB122, BIIB122-Matching Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
30 Years to 80 Years
Enrollment
650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
33
States / cities
Phoenix, Arizona • Sun City, Arizona • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 2, 2026, 10:14 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Potential for Gastric-pH Dependent Drug-Drug Interactions of BIIB122 With a Proton Pump Inhibitor in Healthy Participants

NCT06264440
View directory record Official record
Conditions
Healthy Volunteer
Interventions
BIIB122, Rabeprazole
Drug
Lead sponsor
Biogen
Industry
Eligibility
30 Years to 80 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 18, 2024 · Synced Sep 2, 2026, 10:14 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Mass Balance, Pharmacokinetics, Metabolite Profile, and Metabolite Identification of BIIB122/DNL151 in Healthy Male Subjects

NCT05119790
View directory record Official record
Conditions
Healthy Volunteers
Interventions
[14C] BIIB122 ([14C] DNL151)
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 6, 2021 · Synced Sep 2, 2026, 10:14 PM EDT